Compounds and compositions as RAF kinase inhibitors

US10167279B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Robert John Aversa · Cambridge, US
• Matthew Burger · Belmont, US
• Michael Patrick Dillon · Mill Valley, US
• Thomas A. Dineen · Somerville, US
• Yan Lou · Fremont, US
• Gisele Nishiguchi · Arlington, US
• Savithri Ramurthy · Walnut Creek, US
• Alice Rico · Castro Valley, US
• Vivek Rauniyar · Cambridge, US
• Martin Sendzik · Belmont, US
• Sharadha Subramanian · San Ramon, US
• Lina Q. Setti · Fremont, US
• Benjamin R. TAFT · Lafayette, US
• Huw Rowland Tanner · San Francisco, US
• Lifeng Wan · Richmond, US

Key dates

• Filing date: Sep 11, 2015
• Grant date: Jan 1, 2019
• Expiry date: Sep 11, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D413/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.